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Identity 
Other names: Dig2, REDD-1, REDD1 




The DDIT4 gene encompasses 2,1 kb, containing 3 
exons. Exon 1 includes 142 nucleotides and is non-
coding, exon 2 (265 nucleotides) codifies for the first 
65 amino acids, and exon 3 (1345 nucleotides) codifies 
for the remaining 167 amino acids and contains the 3' 
UTR (NM_019058.2). 
Transcription 
A single mRNA of 1748 nucleotides is expressed from 
the plus strand and includes a 699 coding sequence, a 
201 5' UTR and a 848 3' UTR (ENST00000307365, 
Ensembl Genome Browser database). Note minor 
discrepancy in non-coding region (4 nucleotides) 
between NCBI and Ensembl annotation. 
Protein 
Note 
REDD1 is a highly conserved protein of 232 amino 
acids, with a predicted molecular weight of 25 kDa. 
Apparent molecular weight on SDS-PAGE is 35 kDa. 
Amino acid sequence analyses do not show any known 
structural or functional domains. The crystal structure 
revealed a new fold and a conserved surface patch that 
is essential for function (Vega-Rubin-de-Celis et al.,
2010). 
Description 
REDD1 is conserved from insects to humans, 
especially in the C-terminal region (Vega-Rubin-de-
Celis et al., 2010).  
The N-terminal 84 amino acids of REDD1 are 
dispensable for function. The REDD1 crystal structure 
includes residues 89-226 and has a deletion of a few 
hydrophobic residues (200-204) that are dispensable for 
function (Vega-Rubin-de-Celis et al., 2010).  
The REDD1 protein has two antiparallel α-helices 
followed by a mixed β-sheet, containing 4 β-strands 
ordered 2134.  
Strands β1-β3 make an unusual structural motif known 
as a psi-loop, two antiparallel strands separated by a 
third that makes hydrogen bonds with the two flanking 
strands. 
A conserved surface patch that is essential for REDD1 
function has been identified. This patch is formed by 
two regions: a loop between helix α2 and strand β1 
(residues 138-141) and residues 218-225, which 
encompass the C-terminal portion of the strand β4. 
REDD1 is an unstable protein, with an estimated half-
life of 5-10 min (Kimball et al., 2008; Katiyar et al., 
2009). REDD1 has been shown to be phosphorylated at 
T23 and T25 and phosphorylation at these sites has 
been postulated to regulate REDD1 half-life. 
These sites are in an N-terminal region that is 
dispensable for mTORC1 inhibition (Vega-Rubin-de-
Celis et al., 2010). 
Based on in vitro kinase assays, it was postulated that 
the kinase implicated in REDD1 phophorylation is 
Glycogen Sinthase Kinase 3β (GSK3β). 
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REDD1 crystal structure (PDB ID: 3LQ9). A) Cartoon diagram of REDD1 (89-226∆200-204) structure colored in rainbow mode from N- 
to C- terminus. Dotted line represents a disordered region. B) REDD1 sequence alignment in different species colored in blue gradient 
according to conservation. Red boxes indicate the sequences forming the conserved functionally important surface patch. C) 
Conservation mapping of REDD1 surface using the blue gradient color as in (B). Modified with permission from Vega-Rubin-de-Celis et 
al., Biochemistry, 2010. Copyright (2010) American Chemical Society. 
 
HA-GSK3β isolated from transfected HEK293 cells 
can phosphorylate GST-REDD1 (Katiyar et al., 2009). 
However, whether GSK3β phosphorylates endogenous 
REDD1 is still unknown. How these phosphorylation 
events are implicated in REDD1 stability is also 
unclear. Katiyar et al. reported a modest increase in 
REDD1 half-life upon treatment with LiCl, a GSK3β 
inhibitor, in HEK293 cells. In addition, REDD1 
T23A/T25A mutants transfected in HEK293 cells are 
more stable than wild-type REDD1. However, 35S 
Methionine/Cysteine pulse-chase experiments in HeLa 
cells suggested that REDD1 wild-type and the 
T23A/T25A mutants have a similar half-life and LiCl 
had no effect on the half-life of endogenous REDD1 in 
these cells (Vega-Rubin-de-Celis and Brugarolas, 
unpublished results). 
REDD1 half-life has been proposed to be regulated by 
the CUL4A-DDB1-ROC1-βTRCP-E3 ubiquitin ligase 
complex (Katiyar et al., 2009). In overexpression 
experiments in HEK293 cells, Flag-REDD1 was found 
to interact with the complex components Myc-CUL4A, 
AU1-DDB1 and HA-βTRCP.  
In addition, endogenous REDD1 was shown to bind to 
DDB1 and βTRCP in MCF-7 cells exposed to hypoxia 
and the proteasome inhibitor MG132 (Katiyar et al.,
2009). Furthermore, knock-down of βTRCP by siRNA 
in MCF-7 cells increased the REDD1 half-life to 25 
minutes (Katiyar et al., 2009). Knock-down of other 
complex components (CUL4A and DDB1) also 
increased REDD1 half-life, but to a lesser extent (10-15 
minutes) (Katiyar et al., 2009). 
Several large-scale proteomic studies showed that 
REDD1 is ubiquitinated at K129 (Meierhofer et al., 
2008; Xu et al., 2010; Danielsen et al., 2011; Kim et 
al., 2011; Lee et al., 2011; Shi et al., 2011; Wagner et 
al., 2011). Whether this modification affects REDD1 
stability (or function) is unknown and K129 is not 
conserved across species. 
Thioredoxin-Interacting protein (TXNIP) has been 
shown to bind to REDD1 and TXNIP overexpression in 
HeLa and H1299 cells increased REDD1 levels (Jin et 
al., 2011). However, these experiments were performed 
with ectopically expressed protein and whether the 
endogenous proteins interact and whether TXNIP 
regulates REDD1 stability remains to be determined. 
A yeast-two hybrid screen of a human leukocyte library 
reported several putative binding proteins (Gery et al., 
2007), and other studies identified other REDD1 
interacting proteins including TXNIP (DeYoung et al., 
2008; Jin et al., 2011). However, none have been 
validated with endogenous REDD1 protein. 
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Expression 
REDD1 is developmentally regulated. Redd1 
expression has a similar pattern as p63, being expressed 
at early stages in the apical ectodermal ridge and l ter
on, at ectoderm-derived tissues (Ellisen et al., 2002). 
Interestingly, p63-/- embryos have lower Redd1 levels 
suggesting that p63 is an important developmental 
regulator of REDD1 (Ellisen et al., 2002). 
REDD1 mRNA is broadly induced in response to 
hypoxia (Shoshani et al., 2002; Wolff et al., 2011). 
Using mice with a gene trap reporter (β-geo) inserted in 
Redd1 intron 2, Wolff et al. showed that Redd1 is 
induced after 1h of hypoxia in most of the tissues 
analyzed, with the exception of cardiac and skeletal 
muscle. Redd1 was broadly induced in endothelial cells
as well as in cells in the crypts of the small bowel, 
bronchial epithelial cells, cells in zone 3 in the liver, 
cells lining the collecting ducts of the kidney, red pulp 
and histiocytes in the spleen and Purkinje cells in the 
cerebellum (Wolff et al., 2011). 
REDD1 is a hypoxia inducible factor (HIF) target 
(Shoshani et al., 2002). HIF-1 and -2 are heterodimeric 
transcription factors containing an α-subunit that is 
regulated by oxygen levels through hydroxylation (Ivan 
et al., 2001; Jaakkola et al., 2001; Masson et al., 2001; 
Yu et al., 2001) and a β-subunit (also called aryl 
hydrocarbon receptor nuclear translocator, ARNT) that
is stable (Semenza, 2006).  
Hydroxylated HIFα is recognized by an ubiquitin ligase 
complex containing the von Hippel-Lindau (pVHL) 
tumor suppressor protein (Cockman et al., 2000; 
Kamura et al., 2000; Ohh et al., 2000; Tanimoto et al., 
2000).  
It has been shown in cell lines and mouse models that 
REDD1 induction is VHL and HIF-dependent 
(Kucejova et al., 2011). REDD1 is a target of both 
HIF1α and HIF2α, as assessed by ChIP assays and 
siRNA experiments in clear cell renal cell carcinoma 
(ccRCC) cell lines 786-O, A498 and Caki-2 (Kucejova 
et al., 2011). 
MEFs deficient for ataxia telangiectasia mutated 
(ATM) are unable to induce HIF1α (and REDD1) in 
response to hypoxia suggesting that, at least in some 
contexts, ATM may be required for HIFα stabilization 
(Cam et al., 2010). 
Besides hypoxia, REDD1 is also induced in response to 
a variety of other stress conditions, including ER stress 
(Wang et al., 2003; Whitney et al., 2009), osmotic 
stress (Wang et al., 2003) and in response to DNA-
damaging agents (Ellisen et al., 2002; Lin et al., 
2005a). Other REDD1 inducers include glucocorticoids 
(Wang et al., 2003; Boldizsar et al., 2006) and all-tr ns-
retinoic acid (ATRA) (Gery et al., 2007). 
Apart from HIF1 and 2, other transcription factors have 
been implicated in REDD1 induction: 
- ATF4 (activating transcription factor 4): REDD1 is
induced under ER stress conditions in an ATF4-
dependent manner (Whitney et al., 2009). Experiments 
performed in HepG2 cells showed REDD1 induction 
with the ER stress inducers Thapsigargin and 
Tunicamycin. This induction was shown to be protein 
kinase RNA-like ER kinase (PERK) and ATF4-
dependent based on studies on PERK or ATF4-
deficient MEFs. In addition, ectopically overexpress d 
ATF4 was sufficient to induce REDD1 expression in 
HEK293. 
- CREBP (CCAAT/enhancer-binding protein): DNA-
damaging agent MMS induces REDD1 mRNA in 
HaCaT cells in a CREBP-dependent manner (Lin et al., 
2005a). Luciferase reporter assays identified a MMS-
responsive region within -1057/-981 (Lin et al., 2005a) 
which included a putative CREBP site at -1009/-999, 
and CREBP was found to bind to this sequence in 
EMSA. 
- Elk1: REDD1 mRNA is induced in HaCaT cells 
exposed to arsenite, in a Elk1 and CCAAT/enhancer-
binding protein (CREBP)-dependent manner (Lin et al., 
2005b). Luciferase reporter assays in HaCaT cells 
mapped the arsenite-responsive region to the -1057/-
981 (Lin et al., 2005b), and EMSA assays showed 
CREBP binding to that region. 
- NFATc3 (nuclear factor of activated T-cell): in 
intestinal cells REDD1 is induced by the NFAT 
activators PMA and A23187, and siRNA knockdown 
of NFATc3 but not other family members 
compromised PMA/A23187-induced REDD1 
expression (Zhou et al., 2012). Luciferase-reporter 
assays showed that NFATc3 was sufficient to activate 
expression of REDD1 promoter sequences and ChIP 
assays in HT29 cells showed binding of NFATc3 (-
2931/-97) (Zhou et al., 2012). 
- p53: MEFs treated with ionizing radiation induced 
REDD1 in a p53-dependent manner, and 
overexpression of p53 in SAOS and U2OS cells 
induced REDD1 (Ellisen et al., 2002). Luciferase 
reporter assays in U2OS cells identified a p53-
responsive element at -600 bp (Ellisen et al., 2002). 
- Sp1: REDD1 levels are increased in high cell 
densities in a Sp-1 dependent manner (Jin et al., 2007). 
Sp1 siRNA in HeLa cells abolished REDD1 induction 
by high cell density. Sp1 can also contribute to REDD1 
induction in hypoxia or in response to hypoxia 
mymetics (Jin et al., 2007), and siRNA experiments 
compromised CoCl2-dependent REDD1 induction. The 
putative Sp1 binding site was mapped to -476/-446 of 
the REDD1 promoter by luciferase-reporter assays in 
HeLa cells (Jin et al., 2007). 
The REDD1 promoter region contains putative target 
sequences for other transcription factors, including 
NFkB and hepatocyte-nuclear factor 4 (HNF4) (Lin et 
al., 2005b). 
Localisation 
REDD1 has been reported to be localized in both 
nuclear and cytosolic compartments in overexpression 
experiments (Ellisen et al., 2002; Lin et al., 2005b). 
Biochemical fractionation studies of the endogenous 
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protein did not show REDD1 in the nucleus, but 
indicated that REDD1 is both in a cytosolic and a 
membrane compartment (DeYoung et al., 2008). In 
Redd1-/- MEFs transduced with a retroviral vector 
encoding for REDD1, REDD1 localized to the 
mitochondria (Horak et al., 2010). Further studies are
required with the endogenous protein. However, 
preliminary experiments (both in normoxia and 
hypoxia conditions) suggest that REDD1 is in the 
cytosol and that it is peripherally associated with a 
membrane compartment (Vega-Rubin-de-Celis et al., 
unpublished results). 
Function 
REDD1 is induced in hypoxia and is both necessary 
and sufficient for hypoxia-induced mammalian target 
of rapamycin complex 1 (mTORC1) inhibition 
(Brugarolas et al., 2004). MEFs deficient for Redd1 
(Brugarolas et al., 2004; DeYoung et al., 2008; Wolff 
et al., 2011) fail to inhibit mTORC1 in response to 
hypoxia, and depletion experiments with siRNAs or 
shRNA in HeLa, HEK293 and U937 cells 
compromised hypoxia-induced mTORC1 inhibition 
(Corradetti et al., 2005; Gery et al., 2007; Vega-Rubin-
de-Celis et al., 2010). Overexpression of REDD1 in 
multiple cell types including U2OS (Brugarolas et al.,
2004; Sofer et al., 2005; DeYoung et al., 2008; Vega-
Rubin-de-Celis et al., 2010), HeLa (Vega-Rubin-de-
Celis et al., 2010), MEFs (Sofer et al., 2005), and 
HEK293 (Corradetti et al., 2005) cells is sufficient for 
mTORC1 inhibition. 
REDD1 has a paralogue, REDD2 (DDIT4-like 
(DDIT4-L) or RTP801-like (RTP801-L)). REDD1 and 
REDD2 appear to be have originated from a gene 
duplication event that occurred independently in 
humans and insects (Vega-Rubin-de-Celis et al., 2010). 
However, unlike Redd1, Redd2 is not induced by 
hypoxia, at least in MEFs (Wolff et al., 2011). 
Nevertheless, like REDD1, REDD2 overexpression is 
sufficient to inhibit mTORC1 (Brugarolas et al., 2004). 
The Drosophila orthologues, scylla and charybdis, were 
identified in a screen to isolate inhibitors of an 
increased cell size phenotype generated by 
simultaneously expressing PDK1 and Akt (Reiling and 
Hafen, 2004). Both genes contain consensus hypoxia-
response elements (HRE) sequences (Reiling and 
Hafen, 2004). Scylla expression is also induced in 
response to hypoxia in the larval fat body and the gut.
Charybdis mRNA was not induced in the fat body and 
only slightly in the midgut (Reiling and Hafen, 2004). 
In addition, charybdis is not induced through 
overexpression of constitutively active Drosophila 
HIFα (sima) or Hifβ (tgo) (Reiling and Hafen, 2004). 
Even though REDD1 induction broadly inhibits 
mTORC1, under some conditions (and for reasons that 
are not understood), this is not the case in ccRCC. VHL 
is inactivated in a majority of ccRCC cases, leading to 
stabilization of HIF1/HIF2 and increased REDD1  
levels. However, REDD1 does not appear to inhibit 
mTORC1, and mTORC1 is frequently activated in 
ccRCC (Kucejova et al., 2011). 
Hypoxia-induced mTORC1 inhibition is dependent on 
the tuberous sclerosis complex 1 and 2 proteins, which 
form a complex (TSC1/TSC2). This has been shown in 
a variety of systems. Tsc2-/- MEFs fail to inhibit 
mTORC1 when exposed to hypoxia or to ectopic 
Redd1, but they regain their ability to inhibit the 
pathway after Tsc2 reconstitution (Brugarolas et al.,
2004; Corradetti et al., 2005; Sofer et al., 2005). 
Depletion of TSC2 with siRNA in U2OS, HeLa, 
HEK293 and MCF10A cells also compromises 
mTORC1 inhibition by hypoxia or REDD1 
overexpression (Brugarolas et al., 2004; Connolly et 
al., 2006; Vega-Rubin-de-Celis et al., 2010). 
However, hypoxia-induced mTORC1 inhibition can 
also occur independently of mTORC1. In hepatocytes, 
mTORC1 inhibition by hypoxia is REDD1-
independent. In this cell type, hypoxia signals are 
transduced in a manner that is also independent of 
Tsc1/Tsc2 and Hif (Wolff et al., 2011). 
It was suggested that REDD1 acts by sequestering 14-
3-3 proteins from TSC2 thereby activating TSC2 and 
inhibiting mTORC1 (DeYoung et al., 2008). However, 
how REDD1 would selectively sequester TSC2-bound 
14-3-3 versus the whole 14-3-3 pool in the cell, which 
is quite large, is not clear. Furthermore, the putative 14-
3-3 binding site in REDD1 does not conform to any of 
14-3-3 binding sites known (Vega-Rubin-de-Celis et 
al., 2010), and endogenous REDD1 does not seemingly 
bind to 14-3-3 proteins. Moreover, the postulated 14-3-
3 binding motif in REDD1 (133RLAYSEP139) is not 
conserved, and mutations of R133 and S137 that might 
have expected to be critical for 14-3-3 binding do not
abrogate REDD1 function (Vega-Rubin-de-Celis et al., 
2010). 
REDD1 is developmentally regulated in both flies and 
in mice, but Redd1 is dispensable for development in 
mice (Brafman et al., 2004; Yoshida et al., 2010; 
Molitoris et al., 2011; Wolff et al., 2011). In addition, 
loss of both scylla and charybdis does not cause 
lethality in flies. However, their loss severely 
compromised larval survival in hypoxia conditions 
(Reiling and Hafen, 2004). Interestingly, disruption f 
Redd1 in mice does not result in a compensatory 
induction by the paralogue Redd2, which has been 
shown to also inhibit mTORC1 in overexpression 
experiments in HeLa cells (Brugarolas et al., 2004). 
Mutations 
Note 
A frameshift inactivating mutation (c.550delC) was 
found in ccRCC (Kucejova et al., 2011).  
However, no other REDD1 mutations where identified 
in sequencing analyses of 77 tumors. 
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Somatic 
A somatically acquired mutation was identified in a 
pancreatic tumor (c.571G>T; p.G191W) (Sanger 
Institute, COSMIC database). While the residue is not 
conserved, according to PolyPhen-2, the mutation is 
probably damaging, but whether it affects function s 
unclear. 
A mutation in prostate cancer (c.253A>C; p.S85R) has 
been described (Sanger Institute, COSMIC database).  
It is unknown whether the mutation was somatically 
acquired and according to PolyPhen-2 it is probably 
damaging.  
An additional somatically acquired mutation was found 
in prostate carcinoma (c.253A>C); however, it is a 
synonymous substitution (p.L96L) (Sanger Institute, 
COSMIC database). 
Two mutations have been detected in lung squamous 
cell carcinoma (G75R and A37V) (Hammerman et al., 
2012, cBIO Cancer Genomics). They are both 
somatically acquired (Sanger Institute, COSMIC 
database), and according to PolyPhen-2 they are 
predicted to be benign. 
Two mutations have been identified in uterine corpus 
endometrioid carcinoma (H91R and R143W) (cBIO 
Cancer Genomics).  
They are somatically acquired, (Sanger Institute, 
COSMIC database) and according to PolyPhen-2 they 
are predicted to be benign (H91R) or probably 
damaging (R143W). 
A somatically acquired mutation was identified in two 
samples of lung carcinoma (c.4C>T; p.P2S) (Sanger 
Institute, COSMIC database). Pro2 residue is in a 
dispensable region in REDD1; however, according to 
Polyphen2 is probably damaging. 
A synonymous somatically acquired substitution 
mutation was also described in lung carcinoma 
(c.561C>G; p.P187P) (Sanger Institute, COSMIC 
database). 
A somatically acquired mutation was identified in 
cervix carcinoma (c.79G>C; p.D27H) (Sanger Institute, 
COSMIC database).  
It is in a dispensable region in REDD1 and predicte to 
be benign based on Polyphen2. 
In urinary tract carcinoma samples a somatically 
acquired mutation was found (c.671C>T; p.S224L) 
(Sanger Institute, COSMIC database).  




DDIT4 has been shown to be mutated in a handful of 
cancers at low frequency. However, mutations may not 
be detrimental and while it would be fitting for a 
negative mTORC1 regulator to act as a tumor 
suppressor, whether this is the case remains to be 
determined and no tumor predisposition has been 
reported in Ddit4-deficient mice.  
Interestingly, REDD1 is over expressed in most of the 
ccRCC tumors, due to the loss of pVHL and 
HIF1/HIF2 stabilization. Paradoxically this increas 
does not lead to mTORC1 inhibition, and mTORC1 is 
usually activated in ccRCC (Kucejova et al., 2011). 
Viral infection 
Note 
REDD1 has been recently implicated as a host defens 
factor in response to viral infections. In Redd1-/- 
MEFs, there is increased viral protein translation after 
viral infection in a mTORC1 dependent manner (Mata 
et al., 2011). Treatment with Rapamycin 
downregulated viral proteins in both Redd1+/+ and 
Redd1-/- MEFs, suggesting that the mTORC1 is 
implicated in viral protein synthesis. Naphthalimides 
(which inhibit NS1, an influenza A virus virulence 
factor) induce REDD1 and inhibit mTORC1 thereby 
reducing viral protein production. REDD1 may be 
essential for their antiviral effect, as the antiviral effect 
was abolished in Redd1-/- cells. Similarly, in Tsc2-/- 




Redd1 was found to be increased in cellular and anim l 
models of Parkinson disease (Malagelada et al., 2006; 
Malagelada et al., 2008). It has been shown to increase 
neuronal cell death through a mechanism involving 
mTORC1 and Akt. In PC12 cells treatment with 
6OHDA induces Redd1 and increases cell death; this 
phenotype is rescued by knock-down of Redd1. 
Furthermore, Redd1 overexpression is sufficient to 
induce cell death. 
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